Company intelligence / Profile preview
BioMarck Pharmaceuticals, Ltd.
Newtown, Pennsylvania, United Statesbiomarck.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BIO-11006 demonstrated safety and a 43% reduction in all-cause mortality at 28 days in ARDS Phase 2a trial. In the Phase 2 clinical study for ARDS, rapid improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo, along with decreases in pro-inflammatory cytokines. At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.
- Therapeutic areas
- OncologyPulmonologyImmunology
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on BioMarck Pharmaceuticals, Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMarck Pharmaceuticals, Ltd..